Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trialsGary Lichtenstein, William J. Sandborn, A. Olson et al.|Alimentary Pharmacology & Therapeutics|2009Cited by 195
T1142 Infliximab Treatment for Ulcerative Colitis: Clinical Response, Clinical Remission, & Mucosal Healing in Patients with Moderate or Severe Disease in the Active Ulcerative Colitis Trials (ACT1 & ACT2)Daniel H. Present, Omar Dabbous, William J. Sandborn et al.|Gastroenterology|2008Cited by 3